[go: up one dir, main page]

AR054789A1 - Antagonistas del receptor 1 de triazolopiridina canabinoide - Google Patents

Antagonistas del receptor 1 de triazolopiridina canabinoide

Info

Publication number
AR054789A1
AR054789A1 ARP060102640A ARP060102640A AR054789A1 AR 054789 A1 AR054789 A1 AR 054789A1 AR P060102640 A ARP060102640 A AR P060102640A AR P060102640 A ARP060102640 A AR P060102640A AR 054789 A1 AR054789 A1 AR 054789A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
aryl
heterocyclyl
heteroaryl
group
Prior art date
Application number
ARP060102640A
Other languages
English (en)
Inventor
Chongqing Sun
Philip M Sher
Gang Wu
William R Ewing
Yanting Huang
Taekyu Lee
Natesan Murugesan
Richard B Sulsky
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR054789A1 publication Critical patent/AR054789A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas que los contienen y usos como agentes antiobesidad y antidiabético, entre otros. Reivindicacion 1: Un compuesto o un profármaco o un solvato o una sal aceptable o un estereoisomero del mismo caracterizado porque tiene la formula (1) donde: R1 se selecciona del grupo que consiste de hidrogeno, halogeno, ciano, arilo, heteroarilo, alquilo, alquenilo, alquinilo, heterociclilo, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7OR8, NR7COR8. NR7CO2R8, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, y CONR7R8, cualquiera de los cuales puede ser opcionalmente substituido con 1 hasta 3 R10; R2 se selecciona del grupo que consiste de arilo y heteroarilo, cualquiera de los cuales puede ser opcionalmente substituido con 1 hasta 3 R10; R3 se selecciona del grupo que consiste hidrogeno, halogeno, ciano, arilo, heteroarilo, alquilo, alquenilo, alquinilo, heterociclilo, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, y CONR7R8, cualquiera de los cuales puede ser opcionalmente substituido con 1 hasta 3 R10; R4 se selecciona de grupo que consiste de hidrogeno, halogeno, ciano, arilo, heteroarilo, alquilo, alquenilo, alquinilo, heterociclilo, OR6, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, y CONR7R8, cualquiera de los cuales puede ser opcionalmente substituido con 1 hasta 3 R10; con la condicion de que al menos uno de R1, R2, R3, y R4 es arilo, el cual puede ser opcionalmente substituido con 1 hasta 3 R10; R5 se selecciona del grupo que consiste de alquilo, alquenilo, alquinilo, y heterociclilo, cualquiera de los cuales puede ser opcionalmente substituido con 1 hasta 3 R10, con la condicion de que R5 no es opcionalmente substituido 2-[4-(indol-3- il)piperidin-1-il]etilo, 2-[4-(indol-3-il)-3,6-dihidro-2H-piridín-1-il]etilo, 3-(4-(indol-3- il)piperidin-1-il]propilo, 3-[4-(indol-3-il)-3,6-dihidro-2H-piridin-1-il]propilo, 4-(4-(indol-3-il)piperidin-1-il]butilo, o 4-[4-(indol-3-il)-3,6-dihidro-2H-piridin-1-il]butilo; R6 se selecciona del grupo que consiste de arilo, heteroarilo, alquilo, alquenilo, alquinilo, y heterociclilo, cualquiera de los cuales puede ser opcionalmente substituido con 1 hasta 3 R10; R7, R8, y R9 son independientemente seleccionados del grupo que consiste de hidrogeno, arilo, heteroarilo, alquilo, alquenilo, alquinilo, y heterociclilo, cualquiera de los cuales puede ser opcionalmente substituido con 1 hasta 3 R10; en donde cualesquiera dos de R6, R7, R8, y R9 pueden opcionalmente juntos formar un anillo cicloalquilo, cicloalquenilo, o heterociclilo de 4 hasta 7 miembros o un anillo de heteroarilo de 5 hasta 6 miembros; R10 en cada caso es independientemente seleccionado del grupo que consiste de arilo, heteroarilo, alquilo, alquenilo, alquinilo, heterociclilo, OR6, OCOR7, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR7, CO2R6, CONR7R8, halogeno, ciano, hidroxilo, carboxilo, y los grupos divalentes oxo (=O) y oximato (=NOR7), cualquiera de los cuales puede ser opcionalmente substituido con 1 hasta 3 R11; R11 en cada caso es independientemente seleccionado del grupo que consiste de arilo, heteroarilo, alquilo, alquenilo, alquinilo, heterociclilo, OR6, OCOR7, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR7, CO2R6, y CONR7R8, halogeno, ciano, hidroxilo, carboxilo, y los grupos divalentes oxo (=O) y oximato (=NOR7), cualquiera de los cuales puede ser opcionalmente substituido con 1 hasta 3 R12; R12 en cada caso es independientemente seleccionado del grupo que consiste de arilo, heteroarilo, alquilo, alquenilo, alquinilo, heterociclilo, OR6, OCORR7, OCONR7R8, OSO2NR7R8, NR7R8, NR7COR8, NR7CO2R6, NR7CONR8R9, NR7SO2R6, NR7SO3R6, NR7SO2NR8R9, SR6, SO2R6, SO2NR7R8, COR6, CO2R6, y CONR7R8, halogeno, ciano, hidroxilo, carboxilo, y los grupos divalentes oxo (=O) y oximato (=NOR7).
ARP060102640A 2005-06-17 2006-06-20 Antagonistas del receptor 1 de triazolopiridina canabinoide AR054789A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69204305P 2005-06-17 2005-06-17
US11/454,322 US7572808B2 (en) 2005-06-17 2006-06-16 Triazolopyridine cannabinoid receptor 1 antagonists

Publications (1)

Publication Number Publication Date
AR054789A1 true AR054789A1 (es) 2007-07-18

Family

ID=37116034

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102640A AR054789A1 (es) 2005-06-17 2006-06-20 Antagonistas del receptor 1 de triazolopiridina canabinoide

Country Status (6)

Country Link
US (1) US7572808B2 (es)
EP (1) EP1891068A1 (es)
AR (1) AR054789A1 (es)
PE (1) PE20070021A1 (es)
TW (1) TW200726765A (es)
WO (1) WO2006138695A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1940821E (pt) * 2005-10-19 2013-05-29 Gruenenthal Gmbh Novos ligandos do receptor de vanilóide e seu uso para a produção de medicamentos
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK2215071T3 (en) 2007-11-30 2015-10-05 Zynerba Pharmaceuticals Inc Prodrugs of tetrahydocannabinol, compositions containing prodrugs of tetrahydrocannabinol, as well as methods of use thereof
CN101910159B (zh) * 2007-12-26 2013-06-19 卫材R&D管理有限公司 杂环取代吡啶衍生物的制备方法
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010018874A1 (en) * 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010093595A1 (en) 2009-02-10 2010-08-19 E. I. Du Pont De Nemours And Company Fungicidal 2-pyridones
EP2464645B1 (en) 2009-07-27 2017-07-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
MX353257B (es) 2009-10-06 2018-01-05 Millennium Pharmaceuticals Inc Star Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
EP2322176A1 (en) * 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
WO2011078360A1 (ja) 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EA026385B9 (ru) * 2010-07-02 2017-08-31 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
KR101360176B1 (ko) 2011-05-04 2014-02-12 제일약품주식회사 신규한 트리아졸로피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
WO2012150829A2 (ko) * 2011-05-04 2012-11-08 제일약품주식회사 신규한 트리아졸로피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
ES2785475T3 (es) 2011-05-10 2020-10-07 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores de canales iónicos
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9266881B2 (en) 2011-11-14 2016-02-23 Merck Sharp & Dohme Corp. Triazolopyridinone PDE10 inhibitors
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
SG10201806846RA (en) 2014-02-13 2018-09-27 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9866684B2 (en) * 2015-02-16 2018-01-09 Microsoft Technology Licensing, Llc Process for real-time data exchange between users on a phone call
PH12017501817B1 (en) 2015-04-03 2023-06-16 Incyte Holdings Corp Heterocyclic compounds as lsd1 inhibitors
TWI765860B (zh) 2015-08-12 2022-06-01 美商英塞特公司 Lsd1抑制劑之鹽
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
EP3246313A1 (en) 2016-05-19 2017-11-22 Solvay Sa Process for the manufacture of 2-substituted-5-(1-methylthio)alkylpyridines
WO2019043635A1 (en) 2017-09-01 2019-03-07 Richter Gedeon Nyrt. COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
CN117820295B (zh) * 2024-03-05 2024-12-20 天津凯莱英医药科技发展有限公司 3-溴-1-（3-氯吡啶-2-基）-1h-吡唑-5-甲酰氯的连续合成方法和系统

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) * 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (es) * 1974-06-07 1981-03-18
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DE2951135A1 (de) * 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) * 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
ATE60571T1 (de) 1984-12-04 1991-02-15 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
KR900001212B1 (ko) 1985-10-25 1990-02-28 산도즈 파마슈티칼스 코오포레이숀 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
IE63760B1 (en) 1987-05-22 1995-06-14 Squibb & Sons Inc Phosphorus-containing HMG-CoA reductase inhibitors
US4759923A (en) * 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4924024A (en) * 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US4871721A (en) * 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) * 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GEP20001939B (en) 1992-01-17 2000-02-05 Angelini Ricerca S P A Soc Consortile Alkyl Derivatives of Trazodone with CNS Activity
US5447954A (en) * 1992-05-05 1995-09-05 Smithkline Beecham P.L.C. Phenylderivate as inhibitors of ATP citrate lyase
US5712396A (en) * 1992-10-28 1998-01-27 Magnin; David R. α-phosphonosulfonate squalene synthetase inhibitors
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5662934A (en) 1993-01-05 1997-09-02 Najarian; Thomas Compositions and methods for lowering cholesterol while maintaining antioxidant levels
DE69324504T2 (de) * 1993-01-19 1999-08-26 Warner-Lambert Co. Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
ATE344279T1 (de) 1995-12-13 2006-11-15 Univ California Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors
IL117702A0 (en) 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
DE19622222A1 (de) 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
US6537987B1 (en) 1996-06-20 2003-03-25 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
US6635626B1 (en) * 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
TR200000946T2 (tr) 1997-10-08 2000-07-21 Sankyo Company Limited İkameli füzyonlu heterosiklik bileşimi
ES2324846T3 (es) * 1998-03-04 2009-08-17 Bristol-Myers Squibb Company Inhibidores de la proteina tirosina quinasa de imidazopirazina heterociclo-sustituida.
SK18822000A3 (sk) 1998-07-06 2001-12-03 Bristol-Myers Squibb Company Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora
WO2000015201A2 (en) 1998-09-10 2000-03-23 Forbes Medi-Tech Inc. Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other disorders
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
WO2000030665A1 (en) 1998-11-25 2000-06-02 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
EP1133474B1 (en) * 1998-12-04 2007-02-21 Bristol-Myers Squibb Company 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
ES2261187T3 (es) 1999-02-24 2006-11-16 The Johns Hopkins University Composiciones y metodos para modular el colesterol serico.
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
AR041268A1 (es) 2002-09-19 2005-05-11 Solvay Pharm Bv Derivados de la 1h -1,2,4- triazol-3-carboxamida que tienen actividad agonista, agonista parcial, agonista inversa o antagonista del receptor cb 1 de cannabinoide y composiciones farmaceuticas que los contienen
WO2005037197A2 (en) 2003-10-06 2005-04-28 Glaxo Group Limited Preperation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
PL1679003T3 (pl) 2003-10-31 2015-09-30 Ishihara Sangyo Kaisha Kompozycja bakteriobójcza i sposób zwalczania chorób roślin
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists

Also Published As

Publication number Publication date
WO2006138695A1 (en) 2006-12-28
TW200726765A (en) 2007-07-16
PE20070021A1 (es) 2007-02-11
US20070004772A1 (en) 2007-01-04
EP1891068A1 (en) 2008-02-27
US7572808B2 (en) 2009-08-11

Similar Documents

Publication Publication Date Title
AR054789A1 (es) Antagonistas del receptor 1 de triazolopiridina canabinoide
AR071763A1 (es) Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20090057A1 (es) Compuestos y composiciones como moduladores de la actividad gpr119
AR076460A1 (es) Antagonistas del receptor cxcr3
AR076859A1 (es) Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20080676A1 (es) Derivados de indol como antagonistas del receptor de glucagon
AR072184A1 (es) Derivados de oxadiazol como agonistas del receptor s1p1
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
PE20061096A1 (es) Derivados de oxiindol como agonistas 5-ht4
CR9690A (es) 3-acilaminobenzanilidas insecticidas
AR073450A1 (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
AR057626A1 (es) Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor
AR054814A1 (es) Derivados de piridazina
AR069814A1 (es) Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen
PE20120135A1 (es) Piperidinas sustituidas como antagonistas de ccr3
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
AR056103A1 (es) Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1
AR069480A1 (es) Derivados de 2-amino-pirimidina
PE20180121A1 (es) Imidazopirazinonas como inhibidores de pde1

Legal Events

Date Code Title Description
FB Suspension of granting procedure